Strides Pharma Science Ltd Upgraded to Hold by MarketsMOJO on Improved Technicals and Valuation

Technical Trend Shift Spurs Upgrade

The primary catalyst for the rating change was a positive revision in the technical grade. Strides Pharma’s technical trend has transitioned from sideways to mildly bullish, signalling a more favourable momentum in the stock’s price action. On a daily basis, moving averages have turned mildly bullish, supporting the recent upward price movement, with the stock closing at ₹1,044.00 on 27 July 2026, up 2.45% from the previous close of ₹1,019.00.

However, the technical picture remains mixed across different timeframes and indicators. The weekly MACD is mildly bearish, while the monthly MACD is bullish, indicating some divergence in momentum. The Relative Strength Index (RSI) shows no signal on the weekly chart but is bearish monthly, suggesting caution. Bollinger Bands are mildly bearish weekly but mildly bullish monthly, and the KST indicator is mildly bearish on both weekly and monthly charts. Dow Theory trends show no clear direction, and On-Balance Volume (OBV) is neutral weekly but mildly bearish monthly.

Despite these nuances, the overall technical grade improvement reflects a more constructive short-term outlook, justifying the upgrade from Sell to Hold.

Valuation Moves from Very Attractive to Attractive

Alongside technical improvements, Strides Pharma’s valuation grade was upgraded from very attractive to attractive. The company currently trades at a price-to-earnings (PE) ratio of 16.63, which is significantly lower than many of its pharmaceutical peers such as Gland Pharma (PE 38.38) and Wockhardt (PE 100.96). The enterprise value to EBITDA ratio stands at 12.08, also comparatively modest within the sector.

Other valuation metrics include a price-to-book value of 3.10 and an enterprise value to capital employed ratio of 2.40, underscoring a reasonable price relative to the company’s asset base and earnings power. The return on capital employed (ROCE) is a healthy 15.54%, while return on equity (ROE) is 18.64%, both indicating efficient use of capital and shareholder funds.

Despite the attractive valuation, the PEG ratio is reported as zero, which may reflect a lack of consensus on growth expectations or data limitations. Dividend yield data is not available, which is typical for growth-oriented pharmaceutical companies reinvesting earnings.

Overall, the valuation upgrade reflects a more balanced view of the stock’s price relative to its earnings and capital efficiency, supporting the Hold rating.

Financial Trend: Strong Recent Performance Counters Long-Term Concerns

Strides Pharma has demonstrated very positive financial results in the latest quarter (Q4 FY25-26), with net profit growth of 54.96% and a 73.82% increase in PAT over the last six months to ₹337.45 crores. The company has reported positive results for 11 consecutive quarters, signalling consistent operational strength.

Operating profit to interest coverage ratio reached a high of 5.77 times, and half-year ROCE improved to 17.96%, both indicating robust profitability and efficient capital use. These factors have contributed to the positive financial trend underpinning the rating upgrade.

However, some long-term fundamental weaknesses remain. The average ROCE over the longer term is a modest 8.83%, and net sales have grown at a compound annual rate of 7.94% over five years, with operating profit growth at 11.02%. The company’s debt servicing ability is constrained by a relatively high Debt to EBITDA ratio of 1.90 times, which may limit financial flexibility.

Despite these concerns, the recent strong quarterly and half-year performance has improved the financial trend sufficiently to support the Hold rating.

Technical and Market Performance in Context

Strides Pharma’s stock price has shown resilience over longer periods, outperforming the Sensex benchmark significantly. Year-to-date, the stock has returned 15.70%, compared to a Sensex decline of 9.84%. Over one year, the stock gained 14.80% while the Sensex fell 5.68%. The three-year return is particularly impressive at 380.79%, dwarfing the Sensex’s 15.95% gain.

However, the 10-year return of 90.70% trails the Sensex’s 174.18%, reflecting some challenges in sustaining long-term growth. The stock’s 52-week high is ₹1,231.45, with a low of ₹769.60, and the current price of ₹1,044.00 sits comfortably above the midpoint, indicating moderate upside potential.

Short-term price movements have been mixed, with a one-week decline of 1.32% and a one-month drop of 3.61%, both slightly worse than the Sensex’s respective declines of 1.12% and 0.34%. This volatility aligns with the mixed technical signals observed.

Promoter Share Pledging Raises Caution

One notable risk factor is the high level of promoter share pledging, which currently stands at 38.1%. This represents an increase of 10.83% over the last quarter. High pledged shares can exert downward pressure on stock prices during market downturns, as forced selling may occur if margin calls arise.

Investors should monitor this metric closely, as it could impact the stock’s risk profile despite the recent upgrade.

Summary: Balanced Hold Rating Reflects Mixed Signals

The upgrade of Strides Pharma Science Ltd’s investment rating from Sell to Hold reflects a nuanced assessment of multiple factors. Improved technical indicators, particularly the shift to a mildly bullish trend and supportive moving averages, have enhanced the stock’s momentum outlook. Valuation metrics now appear attractive relative to peers, supported by solid returns on capital and reasonable price multiples.

Financially, the company’s recent quarters have been very strong, with robust profit growth and operational efficiency. However, longer-term fundamental challenges such as modest average ROCE, moderate sales growth, and elevated debt levels temper enthusiasm. The high proportion of pledged promoter shares adds an additional layer of risk.

Investors should weigh these factors carefully. While the stock has outperformed benchmarks over recent years and offers an attractive valuation entry point, the mixed technical signals and fundamental concerns suggest a cautious stance. The Hold rating appropriately reflects this balance, signalling neither a strong buy nor a sell recommendation at present.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →